Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis. - Trial NCT06364176
Access comprehensive clinical trial information for NCT06364176 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Kansas Medical Center and is currently Not yet recruiting. The study focuses on Cystic Fibrosis. Target enrollment is 42 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Kansas Medical Center
Timeline & Enrollment
Phase 2
May 01, 2024
Oct 01, 2027
Primary Outcome
Sweat chloride
Summary
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF)
 on modulator therapy. The main question it aims to answer is if treatment with losartan
 improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator
 therapy.
 
 Participants will be asked take losartan or placebo for twelve weeks and will have changes in
 sweat chloride levels measured as a marker of CFTR function.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364176
Non-Device Trial